Combination therapy with bosentan and metformin in PAH‐CHD patients improved exercise capacity and pulmonary haemodynamics, compared with bosentan alone. Additionally, in vitro decreased pulmonary artery contraction is possibly related to increased AMPK phosphorylation. The gene discussed is PRKAA1; the disease is pulmonary arterial hypertension.